PepGen (NASDAQ:PEPG - Get Free Report) had its price objective dropped by equities researchers at HC Wainwright from $14.00 to $8.00 in a research note issued to investors on Thursday,Benzinga reports. The firm presently has a "buy" rating on the stock. HC Wainwright's price target points to a potential upside of 449.83% from the stock's current price.
PepGen Price Performance
NASDAQ:PEPG traded down $0.01 during trading hours on Thursday, hitting $1.46. 68,702 shares of the company were exchanged, compared to its average volume of 829,313. PepGen has a 52-week low of $0.88 and a 52-week high of $19.30. The stock has a market capitalization of $47.61 million, a price-to-earnings ratio of -0.49 and a beta of 1.39. The company's 50 day moving average price is $1.41 and its 200-day moving average price is $2.47.
PepGen (NASDAQ:PEPG - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.92) EPS for the quarter, missing the consensus estimate of ($0.72) by ($0.20). On average, equities analysts predict that PepGen will post -2.73 earnings per share for the current year.
Insider Activity
In other PepGen news, CEO James G. Mcarthur bought 41,500 shares of the firm's stock in a transaction that occurred on Tuesday, April 8th. The stock was bought at an average cost of $1.15 per share, for a total transaction of $47,725.00. Following the completion of the transaction, the chief executive officer now directly owns 103,913 shares of the company's stock, valued at approximately $119,499.95. This trade represents a 66.49% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 5.20% of the company's stock.
Institutional Investors Weigh In On PepGen
Several hedge funds and other institutional investors have recently added to or reduced their stakes in PEPG. XTX Topco Ltd purchased a new stake in shares of PepGen in the first quarter worth about $25,000. China Universal Asset Management Co. Ltd. acquired a new position in PepGen in the fourth quarter valued at approximately $26,000. ADAR1 Capital Management LLC purchased a new stake in PepGen in the 1st quarter worth approximately $29,000. Corton Capital Inc. purchased a new stake in PepGen in the 4th quarter worth approximately $68,000. Finally, AQR Capital Management LLC acquired a new stake in shares of PepGen during the 1st quarter worth approximately $122,000. 58.01% of the stock is owned by institutional investors and hedge funds.
About PepGen
(
Get Free Report)
PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.
Featured Articles
Before you consider PepGen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PepGen wasn't on the list.
While PepGen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
